A public body that develops and provides guidance to UK healthcare professionals and others, to ensure that the care they provide is of the best possible quality and offers the best value for money.
Widening access to cell and gene therapies could result in economic gains of over £20 billion for the UK within a decade, according to a new report...
A new algorithm-based surveillance test for ovarian cancer is being offered on the NHS to women carrying BRCA1 or BRCA2 mutations...
The National Institute for Health and Care Excellence recommends three NHS-funded IVF cycles for those eligible under 40, with potential for three more if unsuccessful, in a proposed guideline update...
Targeted weight loss programmes could improve the IVF outcomes in prospective mothers with obesity, a review from the University of Oxford has revealed...
Hundreds are set to receive the first-ever treatment licensed across Great Britain for a rare mitochondrial disease...
NHS Greater Manchester is consulting on a proposal to harmonise the number of NHS-funded IVF cycles offered across the region, meaning a reduction in cycles for some residents...
This PET event explored pregnancy loss in relation to fertility treatment, including how to reduce risks and provide appropriate support...
Gene therapy, Casgevy, has been recommended for use on the NHS in England for some people living with a severe form of sickle cell disease...
Elevidys, a gene therapy for Duchenne muscular dystrophy, remains under review in the EU and the UK...
Subscribe for free to what PET does best – informing you of the latest in fertility, genomics and embryo research.
